Comparison of uninterrupted anticoagulation with dabigatran etexilate or warfarin in the periprocedural period for atrial fibrillation catheter ablation: Results of the Japanese subgroup of the RE‐CIRCUIT trial

Journal of Arrhythmia

Matias Nordaby¹  Kenshi Fujii²  Masato Watarai³  Yukihiko Yoshida⁴  Yasuya Inden⁵  Atsushi Iwasa⁶  Masato Murakami⁷  Kazuhiro Satomi⁸  Masaomi Kimura⁹  Wataru Shimizu^1,10  Yoshimasa Murakami^1,11  Ken Okumura^1,12  Nobuko Yamada^1,13  Tomofumi Nakagawa^1,13 

[1] Boehringer Ingelheim Pharma GmbH & Co. KG Ingelheim am Rhein Germany;Cardiovascular Division Sakurabashi Watanabe Hospital Osaka Japan;Department of Cardiology Aichi Prefectural Welfare Federation of Agricultural Co‐operative Associations Anjo‐kosei Hospital Anjo Aichi Japan;Department of Cardiology Japanese Red Cross Nagoya Daini Hospital Nagoya Aichi Japan;Department of Cardiology Nagoya University Hospital Nagoya Aichi Japan;Department of Cardiology New Tokyo Hospital Matsudo Chiba Japan;Department of Cardiology Shonan Kamakura General Hospital Kamakura Kanagawa Japan;Department of Cardiology Tokyo Medical University Shinjyuku‐ku Tokyo Japan;Department of Cardiology and Nephrology Hirosaki University Hospital Hirosaki Aomori Japan;Department of Cardiovascular Medicine Nippon Medical School Hospital Bunkyo‐ku Tokyo Japan;Division of Cardiology Nagoya City East Medical Center Nagoya Aichi Japan;Division of Cardiology Saiseikai Kumamoto Hospital Kumamoto Japan;Nippon Boehringer Ingelheim Co., Ltd. Shinagawa‐ku Tokyo Japan;

关键词: catheter ablation;    dabigatran;    Japanese;    nonvalvular atrial fibrillation;    uninterrupted anticoagulation;   

DOI  :  10.1002/joa3.12024

来源: DOAJ

【 摘 要 】

Abstract Background There are limited data on uninterrupted anticoagulation with direct oral anticoagulants during catheter ablation for atrial fibrillation (AF), particularly in Japan. We planned a subgroup analysis of the RE‐CIRCUIT study, comparing the use of uninterrupted dabigatran therapy with warfarin therapy during catheter ablation among the Japanese subgroup and with that in the total population. Methods The RE‐CIRCUIT study utilized a prospective, randomized, open‐label, blinded endpoint design, and the primary endpoint was the incidence of major bleeding events (MBEs). Patients were randomized to uninterrupted dabigatran 150 mg twice daily or warfarin. In this study, we analyzed the results in Japanese patients. Results Of 704 enrolled patients in the study, 112 Japanese patients were randomized to dabigatran (n = 65) or warfarin (n = 47). MBEs were experienced by two patients: one in the dabigatran group (1.6%, cardiac tamponade) and one in the warfarin group (2.2%, groin hematoma) (risk difference vs warfarin −0.6%; 95% CI −5.8, 4.7). Within the Japanese subgroup, there were no thromboembolic events in both groups. Conclusion While not designed to show statistical difference between two treatment groups, our results from the Japanese subgroup supported those from the overall population. Furthermore, this study provided clinical information regarding MBE, especially cardiac tamponade, in Japanese patients.

【 授权许可】

Unknown